Back to All Combinations

NRG1 Fusion

Intermediate Prognosis
0.30% Prevalence Level 2B HER2 Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
NRG1 HER3
Treatment Implications

Rare but targetable. Zenocutuzumab shows promise.

Recommended Treatments
Zenocutuzumab
Clinical trials
Treatments to Avoid

No specific contraindications noted

Study References

eNRGy trial

Key Statistics
0.30%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Requires RNA-based NGS detection.
Information

Category: HER2 Pathway

Evidence Level: Level 2B

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.